Literature DB >> 16150544

NMDA receptor antagonist treatment at the time of nerve injury prevents injury-induced changes in spinal NR1 and NR2B subunit expression and increases the sensitivity of residual pain behaviours to subsequently administered NMDA receptor antagonists.

John A Wilson1, Emer M Garry, Heather A Anderson, Roberta Rosie, Lesley A Colvin, Rory Mitchell, Susan M Fleetwood-Walker.   

Abstract

Spinal NMDA receptors (NMDA R) are important in neuropathic sensitisation and acute administration of antagonists can provide temporary attenuation of sensitisation. If establishment of the chronic pain state could be prevented by brief administration of such agents at or around the time of nerve injury (pre-emptive analgesia) it might be possible to avoid many of the unacceptable side effects associated with repeated administration of these or other antagonists. Several reports describe aspects of effective pre-emptive analgesia from NMDA R antagonists in animal models of neuropathic pain. The first aim of the present study was to make a direct comparison of changes in mechanical allodynia, cold allodynia and thermal hyperalgesia following nerve injury, demonstrating their increasing degree of susceptibility to pre-emptive NMDA R antagonist treatment. Secondly, we used immunoblotting and immunohistochemistry to investigate the effects of nerve injury on NMDA receptor subunit expression, revealing increased expression of NR2B, but not NR2A and reduced NR1 in the superficial dorsal horn. These changes were attenuated following NMDA receptor antagonist pre-treatment. Thirdly, we investigated the pharmacological properties of residual mechanical allodynia and cold allodynia that remained after pre-emptive treatment and revealed a greater sensitivity to NMDA R antagonists. These findings indicate that in addition to a marked suppression of thermal hyperalgesia and cold allodynia, pre-emptive treatment with NMDA R antagonist causes a lasting change in spinal NMDA R complexes such that remaining mechanical allodynia should be more effectively targeted by NMDA R antagonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150544     DOI: 10.1016/j.pain.2005.07.005

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  20 in total

Review 1.  Ionotropic glutamate receptors in spinal nociceptive processing.

Authors:  Max Larsson
Journal:  Mol Neurobiol       Date:  2009-10-31       Impact factor: 5.590

2.  A novel substituted aminoquinoline selectively targets voltage-sensitive sodium channel isoforms and NMDA receptor subtypes and alleviates chronic inflammatory and neuropathic pain.

Authors:  Boris Tabakoff; Wenhua Ren; Lauren Vanderlinden; Lawrence D Snell; Christopher J Matheson; Ze-Jun Wang; Rock Levinson; C Thetford Smothers; John J Woodward; Yumiko Honse; David Lovinger; Anthony M Rush; William A Sather; Daniel L Gustafson; Paula L Hoffman
Journal:  Eur J Pharmacol       Date:  2016-05-05       Impact factor: 4.432

3.  Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats.

Authors:  Yuki Mihara; Nobuaki Egashira; Hikaru Sada; Takehiro Kawashiri; Soichiro Ushio; Takahisa Yano; Hiroaki Ikesue; Ryozo Oishi
Journal:  Mol Pain       Date:  2011-01-20       Impact factor: 3.395

4.  NMDA NR2A and NR2B receptors in the rostral anterior cingulate cortex contribute to pain-related aversion in male rats.

Authors:  Ting-Ting Li; Wen-Hua Ren; Xiao Xiao; Jia Nan; Long-Zhen Cheng; Xue-Han Zhang; Zhi-Qi Zhao; Yu-Qiu Zhang
Journal:  Pain       Date:  2009-08-19       Impact factor: 6.961

Review 5.  Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain.

Authors:  Long-Jun Wu; Min Zhuo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

6.  Effect of memantine on the levels of neuropeptides and microglial cells in the brain regions of rats with neuropathic pain.

Authors:  Katsumichi Takeda; Mai Muramatsu; Toshiyuki Chikuma; Takeshi Kato
Journal:  J Mol Neurosci       Date:  2009-08-04       Impact factor: 3.444

7.  D-cycloserine reduces neuropathic pain behavior through limbic NMDA-mediated circuitry.

Authors:  Magali Millecamps; Maria V Centeno; Hector H Berra; Charles N Rudick; Simona Lavarello; Tatiana Tkatch; A Vania Apkarian
Journal:  Pain       Date:  2007-04-20       Impact factor: 6.961

8.  NMDA receptor mediates chronic visceral pain induced by neonatal noxious somatic stimulation.

Authors:  Adrian Miranda; Aaron Mickle; Mitchell Bruckert; Pradeep Kannampalli; Banani Banerjee; Jyoti N Sengupta
Journal:  Eur J Pharmacol       Date:  2014-09-30       Impact factor: 4.432

9.  Tyrosine phosphorylation of the N-Methyl-D-Aspartate receptor 2B subunit in spinal cord contributes to remifentanil-induced postoperative hyperalgesia: the preventive effect of ketamine.

Authors:  Xiaoping Gu; Xiaoli Wu; Yue Liu; Songqin Cui; Zhengliang Ma
Journal:  Mol Pain       Date:  2009-12-30       Impact factor: 3.395

10.  Ketamine does not produce relief of neuropathic pain in mice lacking the β-common receptor (CD131).

Authors:  Maarten Swartjes; Marieke Niesters; Lara Heij; Ann Dunne; Leon Aarts; Carla Cerami Hand; Hyung-Suk Kim; Michael Brines; Anthony Cerami; Albert Dahan
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.